Trial Profile
Efficacy and Safety of Anti-Tumor Necrosis Factor Alpha Therapy in Rasmussen'S Encephalitis: an Open Study
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 02 May 2016
Price :
$35
*
At a glance
- Drugs Adalimumab (Primary)
- Indications Encephalitis
- Focus Therapeutic Use
- 22 Apr 2016 Primary endpoint of decrease of seizure frequency has been met, according to results published in the Epilepsia.
- 22 Apr 2016 Results published in the Epilepsia
- 26 Feb 2016 New trial record